Nearly two decades have passed since the approval of Omnitrope (Somatropin) in April 2006, the first biosimilar authorized in Europe. As the pace of biosimilar approvals accelerates globally, the debate around the most effective and timely pathway to market remains ongoing.
As our knowledge of both innovative and biosimilar biologic active substances increases, there is potential scope for streamlining aspects of the biosimilar regulatory requirements for specific data necessary to be included in the submitted dossier. Defining which types of data need to be included and what can be excluded requires clear regulatory guidance.
To pave the way for more efficient regulation, several regulatory authorities have already adopted guidelines that, in some cases, drop requirements for clinical efficacy trials; for example, the UK MHRA adopted such an approach in 2021. Others are already working on updating their guidelines. Below are some recent developments from three authorities in different regions.
Within Europe, the European Medicines Agency (EMA) has now formally outlined a potential streamlined approach. In April 2025, EMA published a draft of a new guidance document entitled "Reflection paper on a tailored clinical approach in biosimilar development" (1). This maps-out a much more tailored clinical approach to biosimilar development, aiming to refine the regulatory process whilst maintaining their commitment to ensuring high standards of safety, quality and efficacy.
This draft paper suggests that in many cases, biosimilarity can be demonstrated through a combination of comprehensive analytical data, pharmacokinetic studies, and potentially limited clinical data, rather than requiring extensive comparative clinical efficacy trials. This change in requirements could significantly reduce the time and cost associated with biosimilar development.
EMA suggests that a robust comparison of analytical and pharmacokinetic (PK) data between multiple batches of the biosimilar and the reference product may be sufficient to establish biosimilarity in many cases. This would potentially reduce reliance on large-scale clinical efficacy trials.
Emphasizes a “tailored clinical approach” recognizing that the extent of clinical data required should be proportionate to the level of uncertainty about biosimilarity based on prior analytical and PK data. The decision to waive or reduce clinical efficacy studies would be made on a case-by-case basis depending on the strength of the biosimilarity assessment.
Whilst advocating for a more efficient pathway, the EMA also acknowledges ongoing complexities in biosimilar development, and the need to address potential challenges such as those related to immunogenicity and other risk factors.
Inarguably the EMA has gained extensive experience in developing biosimilar regulations and evaluating biosimilar medicines over the past two decades; this reflection paper clearly builds upon their learnings. The public consultation period on this draft closes on September 30, 2025, so time is running out to submit feedback and comments before the finalization of the document. This public consultation period provides an opportunity for various stakeholders i.e. biosimilar developers, healthcare professionals, and patient representatives to contribute their perspectives and shape the future of biosimilar regulation in the EU – don’t miss the opportunity!
On 6 May 2025, India’s responsible authority, the Central Drugs Standard Control Organization (CDSCO) released draft updated guidelines for biosimilars aiming to align with international standards and streamline their biosimilar approval process (2). These guidelines focus on demonstrating similarity to a reference biologic in terms of quality, safety, and efficacy, with an emphasis on leveraging advanced analytical methods and in-vitro studies.
Key features include:
Given regulatory agencies of major countries do not require in-vivo studies, and are moving towards waiving some clinical studies, these revisions reveal a trend towards regulatory harmonization by focusing on strengthening orthogonal analytical tools and in vitro studies to establish biosimilarity. India’s biosimilar guidelines were last updated in 2016. The public consultation window for this update closed on 5 June 2025.
In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) issued a draft revision of one of its biosimilar guidelines for public comment until 30 June 2024. This has subsequently been finalized and published on 17 June 2025, with an implementation date of 17 August 2025. The updated document is titled "Guideline on Quality Considerations for Development and Comparability Assessment of Biosimilars, Version 2.0" (3).
This guideline details requirements for biosimilar process and product development, specifically:
Notably, the SFDA emphasizes that “The nature and extent of comparative pre-clinical or clinical program is considered by the SFDA on a case-by-case-basis….”
The global regulatory landscape for biosimilar authorization continues to evolve, driven not only by the cumulative experience of regulatory authorities but, importantly, by advances in modern analytical technologies. These technologies now allow for the detailed and rapid interrogation of the structure of biological molecules in ways that were not possible two decades ago, and which continue to improve.
In particular, the ability of various advanced mass spectrometric techniques to accurately detect subtle differences in protein structure and post-translational modifications has been the driver in enabling the robust physicochemical characterization required to demonstrate biosimilarity, thus allowing reduced reliance on comparative clinical trials.
Regulatory authorities worldwide will continue to aim for streamlined biosimilar regulations. Many have now acknowledged that ‘state-of-the-art’ orthogonal analytical methods can provide sufficient evidence of structural biosimilarity by utilizing their ability to detect small differences between the biosimilar and its reference product. Such comprehensive analytical data, when coupled with appropriate pharmacokinetic and other clinical studies negate the need for comparative efficacy clinical trials.
Global regulators increasingly recognize the power of advanced analytical methods in biosimilar development; it is clear that appropriate and well-designed comparability studies are key to accelerating market access. With deep expertise in mass spectrometry and a long-standing focus on biosimilar characterization, BioPharmaSpec is your trusted partner for robust, head-to-head analytical comparability studies.
Contact us today to discuss how we can support your biosimilar development with tailored, regulatory-aligned analytical strategies.
